Articles

Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in Duchenne Muscular Dystrophy Patients

January 14, 2015

Sarepta Therapeutics Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics, today announced that it has initiated dosing of SRP-4053 in its first human trial, a Phase I/II study in Duchenne muscular dystrophy (DMD).

Read more

Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy

January 12, 2015

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 168 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD).

Read more

Heart Drugs Offer New Hope to Slow Cardiac Damage in Muscular Dystrophy

December 29, 2014

Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology. - See more at: http://wexnermedical.osu.edu/mediaroom/pressreleaselisting/HeartDrugsOfferNewHopeinMuscularDystrophy#sthash.DPFZUrK6.dpuf

Read more

Stem cells faulty in Duchenne muscular dystrophy, researchers find

December 17, 2014

In a mouse model of Duchenne muscular dystrophy, muscle stem cells express connective-tissue genes associated with fibrosis and muscle weakness, according to a new study.

Read more

Phase 2 Study in Boys 6 - <10 Years of Age with Duchenne Muscular Dystrophy

December 17, 2014

A multi-center clinical study evaluating the safety & tolerability, efficacy, pharmacokinetics (what the body does to a drug) and pharmacodynamics (what a drug does to a body) of the new investigational compound, PF-06252616, in approximately 105 boys diagnosed with Duchenne Muscular Dystrophy (DMD) who are able to walk and climb stairs. This study is designed to support future potential regulatory filings.

Read more
Items 1 - 5 of 80  12345678910Next